Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience

被引:8
|
作者
Carboni, Fabio [1 ]
Federici, Orietta [1 ]
Zazza, Settimio [1 ]
Sperduti, Isabella [2 ]
Valle, Mario [1 ]
机构
[1] IRCCS Regina Elena Natl Canc Inst, Dept Peritoneal Tumors, Via Elio Chianesi 53, I-00144 Rome, Italy
[2] IRCCS Regina Elena Natl Canc Inst, Dept Biostat Unit, Rome, Italy
来源
EJSO | 2021年 / 47卷 / 01期
关键词
Peritoneal carcinomatosis; Cytoreductive surgery; HIPEC; Diaphragmatic surgery; Postoperative results; Chest drains; OVARIAN-CANCER; FLUID THERAPY; OUTCOMES; MORBIDITY; CHEMOPERFUSION; DISEASE;
D O I
10.1016/j.ejso.2020.08.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is an effective treatment for improving prognosis of selected patients with peritoneal carcinomatosis. The addiction of diaphragmatic procedures may increase the incidence of postoperative respiratory complications. Our goal was to evaluate the early postoperative results following diaphragmatic surgery. Methods: Prospectively collected data of patients undergoing diaphragmatic surgery between January 2000 and January 2020 were retrospectively analyzed. Chest drains were routinely placed in all cases. Demographics, clinical and perioperative features were evaluated. Results: The study included 222 patients. Peritoneal stripping and full-thickness resections were performed in 165 and 57 cases, respectively. Women and ovarian tumours represented the vast majority of cases. Overall postoperative mortality and morbidity rates were 1.3% (3 patients) and 43.2% (96 patients), respectively. Specific diaphragmatic surgery-related complications was 9.4% (21 patients). No pleural effusion and pneumothotrax occurred. The incidence of pneumonia was 1.8% (4 patients), each due to systemic bacterial origin, 2 (0.9%) of which required Intensive Care Unit-readmission. Postoperative bleeding was observed in 15 (6.7%) cases, 12 (5.4%) of which required reoperation. A comparison with 105 patients who operated during the same period without diaphragmatic surgery was performed and by multivariate analysis, Peritoneal Cancer Index, histology and overall morbidity resulted significantly associated with diaphragmatic surgery. Conclusion: Diaphragmatic surgery during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is often required in order to obtain complete resection. It may be associated with higher postoperative morbidity, especially bleeding, but routine placement of chest drains may reduce the incidence of adverse respiratory events. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience
    Iversen, L. H.
    Rasmussen, P. C.
    Hagemann-Madsen, R.
    Laurberg, S.
    [J]. COLORECTAL DISEASE, 2013, 15 (07) : E365 - E372
  • [2] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis
    Nesher, Eviatar
    Greenberg, Ron
    Avital, Shmuel
    Skornick, Yehuda
    Schneebaunn, Schlomo
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (11): : 787 - 790
  • [3] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Khan, Hadi M.
    Hanif, Hamza
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (02): : 259 - 261
  • [4] Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience
    Carboni, Fabio
    Federici, Orietta
    Sperduti, Isabella
    Zazza, Settimio
    Sergi, Domenico
    Corona, Francesco
    Valle, Mario
    [J]. CANCERS, 2021, 13 (03) : 1 - 14
  • [5] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly
    Tabrizian, P.
    Jibara, G.
    Shrager, B.
    Franssen, B.
    Yang, M.
    Sarpel, U.
    Hiotis, S.
    Labow, D.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S73 - S74
  • [6] Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Roviello, F.
    Caruso, S.
    Marrelli, D.
    Pedrazzani, C.
    Neri, A.
    De Stefano, A.
    Pinto, E.
    [J]. GIORNALE DI CHIRURGIA, 2011, 32 (04): : 211 - 233
  • [7] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis
    Gammon, David C.
    Dutton, Traci
    Piperdi, Bilal
    Zybert, Jason
    Wolfe, Steven H.
    Nguyen, Erin
    Sbat, Dalia
    Pillarisetty, Venu G.
    Sullivan, Mary
    Whalen, Giles F.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (13) : 1186 - 1190
  • [8] Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis
    Rajeev, Rahul
    Turaga, Kiran K.
    [J]. CANCER CONTROL, 2016, 23 (01) : 36 - 46
  • [9] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Initial Experience
    Bartos, Adrian
    Bartos, Dana
    Raluca, Stoian
    Mitre, Calin
    Hadade, Adina
    Iancu, Ioana
    Cioltean, Cristian
    Iancu, Cornel
    Militaru, Claudia
    Parau, Angela
    Breazu, Caius
    [J]. CHIRURGIA, 2019, 114 (02) : 222 - 233
  • [10] Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with and without Diaphragmatic Resection in Patients with Peritoneal Carcinomatosis
    Nikiforchin, A.
    Gushchin, V.
    Baron, E.
    Sittig, M.
    Nieroda, C.
    Sardi, A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S110 - S111